Search
Minerva Neurosciences Inc
NERVAdd to Watchlist
5.210USD
-0.290-5.27%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
242.73MMarket Cap
LossP/E TTM
More Details of Minerva Neurosciences Inc Company
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development and commercialization of proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company is involved in developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and has exclusive rights to develop and commercialize MIN-301 for the treatment of Parkinson’s disease. It has also co-developed seltorexant for the treatment of insomnia disorder and adjunctive treatment of major depressive disorder (MDD). Seltorexant is an innovative selective orexin 2 receptor antagonist. Its Roluperidone is a compound that has been shown to block serotonin, sigma, and α-adrenergic receptors that are involved in the regulation of mood, cognition, sleep and anxiety. Roluperidone has been designed to block a specific subtype of serotonin receptor called 5-HT2A.
Minerva Neurosciences Inc Info
Ticker SymbolNERV
Company nameMinerva Neurosciences Inc
IPO dateJun 25, 2014
CEOLuthringer (Remy)
Number of employees8
Security typeOrdinary Share
Fiscal year-endJun 25
Address1601 Trapelo Road
CityWALTHAM
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02451
Phone16176007373
Websitehttps://www.minervaneurosciences.com/
Ticker SymbolNERV
IPO dateJun 25, 2014
CEOLuthringer (Remy)
Company Executives of Minerva Neurosciences Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Remy Luthringer, Ph.D.
Dr. Remy Luthringer, Ph.D.
Executive Chairman of the Board of Directors, Chief Executive Officer
Executive Chairman of the Board of Directors, Chief Executive Officer
184.82K
--
Mr. Geoffrey Race
Mr. Geoffrey Race
President
President
51.32K
--
Dr. David J. Kupfer, M.D.
Dr. David J. Kupfer, M.D.
Independent Director
Independent Director
23.94K
--
Mr. Hans Peter Hasler
Mr. Hans Peter Hasler
Independent Director
Independent Director
1.25K
--
Mr. Jan G. van Heek
Mr. Jan G. van Heek
Independent Director
Independent Director
--
--
Mr. Frederick Ahlholm, CPA
Mr. Frederick Ahlholm, CPA
Chief Financial Officer, Senior Vice President, Secretary
Chief Financial Officer, Senior Vice President, Secretary
--
--
Dr. Fouzia Laghrissi-Thode, M.D.
Dr. Fouzia Laghrissi-Thode, M.D.
Independent Director
Independent Director
--
--
Dr. Inderjit Kaul, M.D.
Dr. Inderjit Kaul, M.D.
Director
Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Remy Luthringer, Ph.D.
Dr. Remy Luthringer, Ph.D.
Executive Chairman of the Board of Directors, Chief Executive Officer
Executive Chairman of the Board of Directors, Chief Executive Officer
184.82K
--
Mr. Geoffrey Race
Mr. Geoffrey Race
President
President
51.32K
--
Dr. David J. Kupfer, M.D.
Dr. David J. Kupfer, M.D.
Independent Director
Independent Director
23.94K
--
Mr. Hans Peter Hasler
Mr. Hans Peter Hasler
Independent Director
Independent Director
1.25K
--
Mr. Jan G. van Heek
Mr. Jan G. van Heek
Independent Director
Independent Director
--
--
Mr. Frederick Ahlholm, CPA
Mr. Frederick Ahlholm, CPA
Chief Financial Officer, Senior Vice President, Secretary
Chief Financial Officer, Senior Vice President, Secretary
--
--
Revenue Breakdown
FY2021
FY2020
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, May 10
Updated: Sun, May 10
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Federated Hermes Global Investment Management Corp.
10.98%
Balyasny Asset Management LP
9.14%
Janus Henderson Investors
9.14%
Vivo Capital, LLC
8.29%
Logos Global Management LP
7.11%
Other
55.35%
Shareholders
Shareholders
Proportion
Federated Hermes Global Investment Management Corp.
10.98%
Balyasny Asset Management LP
9.14%
Janus Henderson Investors
9.14%
Vivo Capital, LLC
8.29%
Logos Global Management LP
7.11%
Other
55.35%
Shareholder Types
Shareholders
Proportion
Hedge Fund
27.71%
Investment Advisor/Hedge Fund
24.40%
Venture Capital
15.40%
Investment Advisor
11.80%
Private Equity
4.26%
Corporation
2.74%
Individual Investor
0.60%
Research Firm
0.03%
Other
13.06%
Institutional Shareholding
Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
64
31.80M
71.95%
+29.61M
2025Q4
49
8.29M
19.16%
+6.11M
2025Q3
42
1.98M
28.26%
-175.70K
2025Q2
48
3.52M
50.35%
-247.08K
2025Q1
50
3.52M
50.36%
-205.49K
2024Q4
51
3.66M
52.27%
-624.23K
2024Q3
54
3.69M
57.40%
+418.43K
2024Q2
57
3.64M
56.76%
+303.74K
2024Q1
68
3.68M
57.33%
+358.05K
2023Q4
70
4.01M
62.11%
+650.59K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Federated Hermes Global Investment Management Corp.
5.37M
12.41%
+4.02M
+297.53%
Dec 31, 2025
Balyasny Asset Management LP
4.27M
9.86%
+4.27M
--
Dec 31, 2025
Vivo Capital, LLC
4.32M
9.99%
+4.32M
--
Dec 31, 2025
Logos Global Management LP
3.31M
7.65%
+3.31M
--
Dec 31, 2025
Farallon Capital Management, L.L.C.
2.37M
5.47%
+2.37M
--
Dec 31, 2025
Coastlands Capital LP
2.16M
4.99%
+2.16M
--
Feb 13, 2026
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
Jun 17, 2022
Merger
8→1
Jun 17, 2022
Merger
8→1
Jun 17, 2022
Merger
8→1
Jun 17, 2022
Merger
8→1
Date
Ex-dividend Date
Type
Ratio
Jun 17, 2022
Merger
8→1
Jun 17, 2022
Merger
8→1
Jun 17, 2022
Merger
8→1
Jun 17, 2022
Merger
8→1
